Why Acasti Pharmaceuticals (ACST) Stock Is Up Today

NEW YORK (TheStreet) -- Acasti Pharmaceuticals  (ACST) surged Wednesday after the biopharmaceutical company announced it had completed two trials.

The company, which focuses developing krill oil-based forms of omega-3 phospholipid therapies for treating and preventing cardiometabolic disorders, said it completed the Phase II, double-blind, placebo-controlled TRIFECTA study and the Pharmacokinetic PK trial. These results would be crucial in Acasti's talks with the FDA on approval to conduct a Phase III trial in the U.S.

"The conclusion of the clinical studies is a key milestone in our drug development program and we look forward to obtaining results for the two trials," said Acasti interim president and CEO Andre Godin in a statement.

Must Read: Warren Buffett's 25 Favorite Stocks

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

The stock was up 10.55% to $1.11 at 11:39 a.m. More than 3.2 million shares had changed hands, compared to the average volume of 414,126.

ACST Chart

ACST data by YCharts

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

More from Markets

Fed, Micron, Glaxo and Pfizer, FedEx and Facebook - 5 Things You Must Know

Fed, Micron, Glaxo and Pfizer, FedEx and Facebook - 5 Things You Must Know

Listen for These Words from Federal Reserve Chairman Jerome Powell

Listen for These Words from Federal Reserve Chairman Jerome Powell

Saudi Arabia Is Wishing for Rising Oil Prices to Balance Their Budget

Saudi Arabia Is Wishing for Rising Oil Prices to Balance Their Budget

Jim Cramer: Get Ready for a Wild Ride on This Fed Rate-Hike Day

Jim Cramer: Get Ready for a Wild Ride on This Fed Rate-Hike Day

Stocks Steady Ahead of Fed Decision, Oil Recovers But Signals Slower 2019 Growth

Stocks Steady Ahead of Fed Decision, Oil Recovers But Signals Slower 2019 Growth